Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $145.13 Million |
|---|---|
| Enterprise Value | $71.04 Million |
| Earnings per Share | $-4.3 |
| Beta | 0.39 |
| Outstanding Shares | 80,184,540 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.38 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 75117.81%▲ 898.70% |
|---|---|
| Total Invested | $246.51M▼ 45.56% |
| Investors Holding | 85▲ 18.00% |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the Unit...